NitroMed Looks To 2010 NDA For BiDil XR
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm decides to slash jobs, quit promotion of immediate-release BiDil to fund development and commercialization of extended-release version.
You may also be interested in...
Qnexa REMS Should Deter Off-Label Use Of Components, But Not Place Undue Burden
The Endocrinologic and Metabolic Drugs Advisory Committee voted 20-2 in favor of approving the combination of phentermine and topiramate for weight loss during its second review of Vivus’ application.
Vivus Obesity Pill Scores With Phase III Data, But Still Faces Major Market Hurdles
Qnexa combines two generics, but Vivus Chief Operating Officer Peter Tam says: "We are not concerned about generic substitution."
Vivus Obesity Pill Scores With Phase III Data, But Still Faces Major Market Hurdles
Qnexa combines two generics, but Vivus Chief Operating Officer Peter Tam says: "We are not concerned about generic substitution."